Tempus AI, Inc.
67.615USD
+3.8050 (+5.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TEM.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Price
Reading the stored fundamentals…
Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.
Is the price low against peers, cash flow and analyst targets?
1 of 6 checks could not be assessed (no PEG ratio is stored).
Do analysts expect earnings and revenue to keep growing?
Only 3 of 6 checks could be assessed because the figures they need are not meaningful here and there is no analyst coverage stored; 4 are needed.
Has the business grown and earned good returns on its filed numbers?
Can the balance sheet carry its debt?
Is the dividend decent, covered and steady?
No dividend appears in the stored data, so this axis is left off the shape rather than drawn as zero.
An axis marked n/a has no vertex: it is left out of the shape rather than drawn as zero.
Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.
P/E below peers
Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.
Loss-making over the last twelve months, so there is no P/E to compare.
Did not pass
PEG ratio
The PEG ratio is positive and at most 1.5.
No PEG ratio is stored; it needs analyst growth estimates.
Not assessed
EV/EBITDA below peers
EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.
EBITDA is negative, so there is no EV/EBITDA to compare.
Did not pass
Price/book below peers
Price to book is positive and below the peer median, with peers chosen as for P/E.
Price/book 27.36 against a peer median of 6.30 (8 USD companies in Health Information Services).
Did not pass
Statements: SEC filings, newest period 06/2026.
Peers: P/E against 6 USD companies in Health Information Services; EV/EBITDA against 7 USD companies in Health Information Services; price/book against 8 USD companies in Health Information Services.
Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms
Free cash flow yield
Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.
Free cash flow yield -2.1% against a 4.5% risk-free rate.
Did not pass
Analyst target above price
The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.
Mean analyst target above the last close by 10.8% (18 analysts).
Did not pass
Earnings growth, next year
Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.
Next year's EPS: the base figure is not positive, so a growth rate means nothing.
Not assessed
Earnings growth, this year
Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.
This year's EPS: the base figure is not positive, so a growth rate means nothing.
Not assessed
Revenue growth, next year
Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.
Next year's revenue: consensus up 23.4% (21 analysts).
Passed
Revenue growth, this year
Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.
This year's revenue: consensus up 25.4% (21 analysts).
Passed
Estimates rising
More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.
No analyst estimates are stored for this security.
Not assessed
Revenue growth, latest quarter
Revenue in the latest quarter is at least 8% above the same quarter a year earlier.
Latest-quarter revenue up 21.6% on a year earlier.
Passed
Earnings growth, multi-year
Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).
Net income was not positive in FY2025.
Did not pass
Earnings growth, last year
Net income over the latest twelve months is above the twelve months before it, and positive.
Net income was still a loss (twelve months to 06/2026).
Did not pass
Revenue growth, multi-year
Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).
Revenue grew 58.3% a year, FY2022 to FY2025.
Passed
Return on equity
Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.
Return on equity -67.4%: twelve-month net income over the average equity.
Did not pass
Return on assets
Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.
Return on assets -12.7%: twelve-month net income over the average assets.
Did not pass
Cash earnings
Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.
Operating cash flow was not positive over the last twelve months.
Did not pass
Current ratio
Current assets are at least 1.0x current liabilities. Not applied to financial companies.
Current ratio 3.3x.
Passed
Short-term assets cover long-term liabilities
Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.
Current assets are 0.8x the liabilities due after a year.
Did not pass
Debt to equity
Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.
Total debt is 325% of equity.
Did not pass
Net debt to EBITDA
Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.
Net debt with no positive EBITDA to service it.
Did not pass
Interest cover
Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.
Operating income was not positive.
Did not pass
Cash flow to debt
Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.
Operating cash flow was not positive.
Did not pass
Dividend yield
The dividend yield is at least 2%.
No dividend appears in the stored data.
Not assessed
Payout ratio
Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.
No dividend appears in the stored data.
Not assessed
Free cash flow cover
Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.
No dividend appears in the stored data.
Not assessed
Paid every year
A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.
No dividend appears in the stored data.
Not assessed
No cuts
Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.
No dividend appears in the stored data.
Not assessed
Growing dividend
Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.
No dividend appears in the stored data.
Not assessed